Howe & Rusling’s scPharmaceuticals SCPH Stock Holding History

Howe & Rusling’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-205	Closed	-$1K	–	867
2019 Q4	$1K	Buy	+205	New	+$1.05K	﹤0.01%	782

Other funds holding SCPH

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Howe & Rusling's SCPH Position: Q1 2020 in Review

Howe & Rusling sold out of scPharmaceuticals (SCPH) in Q1 2020, closing a stake of 205 shares — an estimated $1K sold.

Howe & Rusling first reported a position in SCPH in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 33 funds tracked by Wall St. Rank hold SCPH as of Q1 2020.

Howe & Rusling reported no remaining scPharmaceuticals position as of Q1 2020 after selling out during the quarter.
Howe & Rusling sold 205 scPharmaceuticals shares in Q1 2020, an estimated $1K.
Howe & Rusling first reported a position in scPharmaceuticals in Q4 2019 and held it in 1 quarter.
Howe & Rusling's scPharmaceuticals position peaked at $1K in Q4 2019.
33 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2020.

Based on Howe & Rusling's 13F filing for Q1 2020, filed 14 May 2020.